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SHORT REPORT Open Access
Experiences of women in secure care who
have been prescribed clozapine for
borderline personality disorder
Geoffrey L. Dickens1*, Catherine Frogley2,3, Fiona Mason2,4, Katina Anagnostakis2 and Marco M. Picchioni2,5
Abstract
Background: Clozapine is an atypical antipsychotic medicine which can cause significant side-effects. It is often
prescribed off-license in severe cases of borderline personality disorder contrary to national treatment guidelines.
Little is known about the experiences of those who take clozapine for borderline personality disorder. We
explored the lived-experience of women in secure inpatient care who were prescribed clozapine for borderline
personality disorder.
Findings: Adult females (N = 20) participated in audio-taped semi-structured interviews. Transcripts were subject
to thematic analysis. The central themes related to evaluation, wellbeing, understanding and self-management;
for many, their subjective wellbeing on clozapine was preferred to prior levels of functioning and symptomatology,
sometimes profoundly so. The negative and potentially adverse effects of clozapine were explained as regrettable but
relatively unimportant.
Conclusions: When psychological interventions are, at least initially, ineffective then clozapine treatment is likely
to be evaluated positively by a group of women with borderline personality disorder in secure care despite the
potential disadvantages.
Keywords: Clozapine, Borderline personality disorder, Emotionally unstable personality disorder, Thematic analysis
Background
People with borderline personality disorder (BPD)
experience pervasive instability of affect, self-image,
impulse control, behaviour, and relationships [1]. Self-
harm, use of emergency health services, and impulsive
aggression are common [2–5]. Guidelines recommend
psychosocial interventions [6–8], limiting the role of
medicines to crises or psychiatric co-morbidity. Never-
theless, clozapine is commonly prescribed for severely
disturbed BPD patients [9], a controversial practice
both because of its significant side-effect profile, in-
cluding potentially fatal severe neutropenia, and an ab-
sence of supporting randomised controlled trials
(RCTs). Two non-RCT studies found psychotic and de-
pressive symptom-related and global functioning im-
provements among a subset of BPD-patients with
prolonged and/or pronounced psychotic symptoms
[10, 11]. One further study, our own recent retrospect-
ive case-series [12], suggested a number of objective
benefits for women diagnosed with BPD displaying se-
vere symptoms and resident in a secure mental health
service. Despite this, there are currently no published
studies of patients’ personal subjective experiences of tak-
ing clozapine for BPD. In this study we conducted semi-
structured interviews with the same women participants
to explore their personal experience of clozapine.
Methods
Inclusion criteria: women aged 18 to 65 diagnosed with
BPD and treated with clozapine while inpatients at St
Andrew’s Healthcare between 2002 and 2010. Exclusion
criteria: learning disability, diagnosis of schizophrenia or
other psychotic disorder. Consenting participants were
interviewed for up to 1 h. The interview comprised
items about clozapine initiation, and their experience of
taking it. Emerging issues were explored through
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unscripted prompts and cues. Interviews were audio-
recorded, transcribed and subjected to a six stage the-
matic analysis [13]: i) transcripts were read repeatedly;
ii) independent open coding of narrative data; iii) codes
were compared, discussed, and, where necessary, amal-
gamated or split; iv) segments with similar codes were
mapped; v) segments were linked hierarchically into
sub-themes and combined into themes; vi) further re-
coding following review and discussion by the research
team to ensure congruence between the presented ex-
tracts and each theme. Our guiding approach was
essentialist-realist since we assumed that what partici-
pants told us reflected the reality as they saw it.
Results
Thirty women were eligible and 20 agreed to participate
(response rate 67 %). Mean age of participants at cloza-
pine initiation was 27.8 years (SD = 7.8); mean time on
clozapine was 26.5 months (SD = 23.0); 15 (75.0 %) pa-
tients were detained under forensic commitment at initi-
ation and 5 (25.0 %) under civil commitment; almost all
(n = 18, 90.0 %) had a history of previous admissions to
secure services; all had received other antipsychotics
prior to clozapine (Mode = 3; range 1 to 6). Analysis re-
vealed four themes.
Evaluation
Participants described an active personal evaluation of
clozapine’s effects, expressed as a perceived benefit-loss
trade-off. Benefits seemed profound but were not always
articulated precisely:
“It’s just hard to explain the difference, because a lot of
people have noticed the difference with me since I’ve
been on it [clozapine], but it’s hard to explain what it
feels like inside” (P15)
“I wish it had been around years ago. Literally, you
know. It’s been really, really good, it’s been a really
positive experience.” (P8)
“… it closed my emotions off. It closed me off… I
literally closed down. I can’t feel anything. I’m more
like a robot not a woman.” (P20)
Most women mentioned significant side-effects, not-
ably hypersalivation (n = 11 at 6 month follow-up). In
addition, there was a mean weight gain of 7.8 Kg at
6 month follow-up. However, side effect importance ap-
peared comparatively low within an overall positive
evaluation of clozapine.
“In the beginning I was very tired… but I’ve managed
to pull myself out of that… which comes to the second
point, which is becoming overweight. But I have had
weight problems before I went on to clozapine, so it’s
not solely dependent on clozapine. The clozapine
hasn’t helped my weight at all. But I think it, erm, if
it’s managed properly, I think you can control your
weight with clozapine, you know, maybe some
exercise” (P8)
“The weight gain well I deal with that my way, that’s
just an ongoing thing. I do things about that so it’s
alright; it’s not the end of the world is it?” (P20)
Some participants drew positive comparisons between
clozapine and other antipsychotics they had experienced,
all in clozapine’s favour.
“I was taking 40 [mg] olanzapine a day… I was still
struggling, I was still crying, still doing risk behaviours
and everything. Since I got put on clozapine I’ve built
it up slowly and I haven’t done anything since. I’ve
tried loads of drugs, loads and loads of different ones
but clozapine is best out of all of them” (P18)
Wellbeing
Almost all (19/20) participants reported tangible benefits
from taking prescribed clozapine including cognitive and
affective changes:
“I’m not in turmoil anymore. I just see it as what will
be will be and I am who I am…I deal with things a
lot better, it doesn’t raise so many issues… I suppose
my impulse control has gone down, my impulses have
gone down” (P16)
“I used to be like… climbing up the ceiling and then
dropping really flat. That hasn’t happened since the
clozapine” (P19)
Spontaneous comments of behavioural and social im-
provement were made by a substantial proportion of
participants including reduced impulsivity and aggres-
sion/self-harm, and improved relationships. Where clo-
zapine had commenced then stopped participants noted
that the gains made were subsequently lost. One woman
said that clozapine had negatively affected her impulsiv-
ity and interpersonal relationships. Some described be-
coming ‘normal’ while others described something more
profound:
“I’ve always called it the magic pill because other
medications have made me better…but they masked
my illness. But with clozapine it’s not that it makes me
better, it completely turns me into a normal person. It’s
not masking something it takes it away” (P2)
“it’s given me freedom of thought, speech…it’s made me
well…made me happy. It’s made me someone that I’ve
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never been able to be before. I couldn’t hold a
conversation like this years ago, I would have just been
rude, obnoxious, scared…paranoid, self-harming every
day, just like a shell of a person” (P6)
Understanding
This theme encompassed women’s expressed under-
standing of BPD within a medical framework:
“Although we get the depressive thoughts, it isn’t
actually clinical depression so for Borderlines [sic] it
[anti-depressant medication] doesn’t work. So yeah, all
the other medication I’ve been on obviously hasn’t
helped me but in the last 18 months clozapine has
really helped me” (P7)
Participant 3 understood her behaviour, which she de-
scribed as “aggressive and lashing out” prior to clozapine
initiation in illness-defined terms:
“Because I was really poorly. I had really poor
behaviour, but not just because I wanted to be, but
because I couldn’t be anything else”
Some also understood the effects of clozapine through
observation of fellow patients:
“I asked to be put on it. Because I saw what it was like
when the other girls here took it. I just said I wanted
to go on it because it helps the other girls” (P5)
Participants sometimes came to new understanding of
the change attributed to clozapine from feedback from
others:
“One poor nurse, I don’t remember but I was told
afterwards, she said she was scared of me. You don’t
realise how you were before you are put on
clozapine” (P9)
Self-management
Central to self-management was the relationship with
the prescribing psychiatrist who had recommended the
medicine.
“We sat down and they talked to me about my illness,
which is Post Traumatic Stress Disorder and Borderline
Personality Disorder, and that this medication worked
really well in people with my condition, and that they
had been using it for a while and that it’s been really
good and they wanted to try me on it” (P2)
For some clozapine was viewed as the primary method
by which they would continue to manage their BPD,
while some expressed that clozapine facilitated other as-
pects of their care and treatment:
“I wouldn’t ever stop taking it, put it that way. It’s
annoying but I would never stop taking it” (P19)
“I’m really stable and I’ve started applying the skills
that we learn in DBT. If at times I get upset about
anything or whatever, I can quickly bring myself back
to, you know, dealing with things appropriately, rather
than going completely off the rails… And I feel like I
can feel the emotions that I feel but with the clozapine
it helps me to do it in a more balanced way” (P14)
Discussion
The largely positive results are consistent with our recent
study [10] and other non-RCT evidence [10, 11, 14]. They
challenge a universal pharmacology-free BPD-recovery
paradigm. Nevertheless, the congruence was unexpected
since clozapine’s side-effect profile is so marked. Even
serious disadvantages were described matter-of-factly,
and the risks considered tolerable. Only psychosocial
approaches are recommended for BPD. However, some
people experience Dialectical Behaviour Therapy as too
focused on self-harm, and less helpful for self-
confidence, emotions and relatonships [15], the areas
that women in this study reported the most progress
on. In the absence of an RCT, many practitioners
already prescribe clozapine for BPD off-licence [9].
Their practice is increasingly evidence-based and, most
importantly, valued by many patients. The results are
also consistent with data that non-BPD patients pre-
scribed antipsychotics are quick and decisive in their
judgement of them as ‘good’ or ‘bad’ [16]. To reduce
reporting bias, interviews were conducted by an assist-
ant psychologist who had no clinical role with the par-
ticipants. The interview style encouraged reporting of
all experiences, while confidentiality and anonymity
were assured. We invited all eligible patients who had
received clozapine for BPD to take part. It is possible
that the one third who declined were less satisfied,
though that does not negate the experiences of the
other participants. The sample included many detained
women with very complex needs. Clinicians should
communicate clearly with BPD-diagnosed patients
about clozapine treatment. People with BPD seem to be
generally dissatisfied with medication-oriented ap-
proaches [16]. However, it is premature to generalise
findings from medicines in general to clozapine in par-
ticular. Participants were sanguine about their experi-
ence: this suggests that good communication with BPD
patients around the reasons for prescribing clozapine is
essential. Development in the US of a shared risk evalu-
ation and mitigation strategy (REMS) called the
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Clozapine REMS Program which requires central moni-
toring of prescribing, dispensing, and receipt of cloza-
pine should further increase confidence in the safety of
the drug which may assist in aiding balanced decision
+s about. In the absence of gold standard evidence this
study and our related study [12] suggests that thera-
peutic nihilism about this group should be challenged:
severe cases of BPD can be treated successfully, women
value the treatment, and tolerate inconvenience and
side effects because the gains can be profound.
Finally, we cannot overstress the importance of the
need for well-designed RCTs to rigorously test the effi-
cacy of clozapineon all sub-syndromal symptoms of the
disorder in people with moderate to severe BPD.
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